2.34
0.48%
0.03
Precedente Chiudi:
$2.31
Aprire:
$2.34
Volume 24 ore:
47,244
Relative Volume:
0.29
Capitalizzazione di mercato:
$47.76M
Reddito:
-
Utile/perdita netta:
$-42.05M
Rapporto P/E:
-0.3939
EPS:
-5.94
Flusso di cassa netto:
$-35.26M
1 W Prestazione:
-10.03%
1M Prestazione:
+15.48%
6M Prestazione:
-20.78%
1 anno Prestazione:
+103.61%
Protara Therapeutics Inc Stock (TARA) Company Profile
Nome
Protara Therapeutics Inc
Settore
Industria
Telefono
646-844-0337
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Confronta TARA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
TARA | 2.34 | 47.76M | 0 | -42.05M | -35.26M | -5.94 |
VRTX | 449.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.03 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-06-04 | Iniziato | H.C. Wainwright | Buy |
2021-02-17 | Iniziato | Oppenheimer | Outperform |
2020-10-19 | Iniziato | Cowen | Outperform |
2020-07-29 | Iniziato | Guggenheim | Buy |
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
HC Wainwright Analysts Decrease Earnings Estimates for TARA - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 18.1% in October - MarketBeat
Protara Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Protara to Present Key TARA-002 Phase 2 Trial Data for Bladder Cancer Treatment | TARA Stock News - StockTitan
Woodline Partners LP Acquires Shares in Protara Therapeutics Inc - GuruFocus.com
HC Wainwright Reiterates "Buy" Rating for Protara Therapeutics (NASDAQ:TARA) - MarketBeat
Protara Therapeutics Reports Increased R&D Expenses - TipRanks
Protara Therapeutics: Q3 Earnings Snapshot - CT Insider
Protara Therapeutics reports Q3 EPS (50c), consensus (52c) - TipRanks
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Protara Therapeutics: FDA Fast Track Win, Strong Trial Progress Despite Wider Q3 Loss | TARA Stock News - StockTitan
Protara Therapeutics Inc (TARA) Quarterly 10-Q Report - Quartzy
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - GlobeNewswire
FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia
FDA fast tracks Protara's choline chloride therapy - Investing.com
Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance
Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India
Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada
Protara reveals high choline deficiency in PS patients - Investing.com India
Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire
Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily
Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex
A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News
Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart
Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily
Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com
TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World
Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World
Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World
Protara Therapeutics Inc Azioni (TARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):